Table 2 Cox univariate and multivariate analysis of recurrence-free and breast cancer-specific survival according to HMGCoA-reductase expression in all, oestrogen receptor (ER) positive and ER-negative patients.
From: Prognostic impact of tumour-specific HMG-CoA reductase expression in primary breast cancer
Recurrence-free survival | Breast cancer-specific survival | |||
|---|---|---|---|---|
RR (95%CI) | p value | RR (95%CI) | p value | |
All patients | Univariate | Univariate | ||
HMG-CoAR negative | 1.00 | 1.00 | ||
HMG-CoAR positive | 0.57 (0.40 to 0.82) | 0.002 | 0.64 (0.91 to 1.03) | 0.07 |
Multivariate | Multivariate | |||
HMG-CoAR negative | 1.00 | 1.00 | ||
HMG-CoAR positive | 0.60 (0.40 to 0.92) | 0.02 | 0.66 (0.39 to 1.11) | 0.12 |
ER positive | Univariate | Univariate | ||
HMG-CoAR negative | 1.00 | 1.00 | ||
HMG-CoAR positive | 0.46 (0.31 to 0.69) | <0.001 | 0.59 (0.34 to 1.00) | 0.02 |
ER negative | ||||
HMG-CoAR negative | 1.00 | 1.00 | ||
HMG-CoAR positive | 1.68 (0.70 to 4.03) | 0.25 | 2.47 (0.81 to 7.54) | 0.11 |
Term of interaction* | 0.004* | 0.01* | ||
ER positive | Multivariate | Multivariate | ||
HMG-CoAR negative | 1.00 | 1.00 | ||
HMG-CoAR positive | 0.47 (0.30 to 0.73) | 0.001 | 0.67 (0.38 to 1.17) | 0.16 |
ER negative | ||||
HMG-CoAR negative | 1.00 | 1.00 | ||
HMG-CoAR positive | 1.45(0.35 to 5.97) | 0.61 | 2.00 (0.37 to 10.93) | 0.42 |
Term of interaction* | 0.01* | 0.11* | ||